Batch Number: 19380/A - 19380/B Molecular Formula: C78H123N23O23S2 Peptide Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe Research Only: Yes Purity: 99%+ Heavy Metals Report : See Report Endotoxin Test: See report Form: Lyophilised Solid Mixing Water Required: Yes Usage and Storage: AOD9604 is provided in lyophilised powder form for enhanced stability
A recent review that examined the efficacy, safety, and perspective for the future of the once-weekly GLP-1 receptor agonists exenatide, taspoglutide, albiglutide, LY2189265 and CJC-1134-PC, and compared them to the currently available agonists, exenatide BID and liraglutide QD, concluded that the long-acting agonists are not superior compared to the currently used exenatide BID and liraglutide QD regarding weight loss (127).In a separate development, an orally administered PYY3-36 and GLP-1 combination has been formulated using a sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC) carrier (127)
Fr die Information an dieser Stelle werden vor allem Nebenwirkungen bercksichtigt, die bei mindestens einem von 1.000 behandelten Patienten auftreten
Most people are able to feel good enough to return to their normal activities within 2 weeks of their surgery
